

Nectar Lifesciences Ltd.

Ref No. NLL/CS/2014- 616



Dated: 11.08.2014

1. National Stock Exchange of India Limited
'G' Block, Exchange Plaza, Bandra Kurla Complex,
Bandra (East), MUMBAI – 400 051.
2. Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers, Dalal Street,
MUMBAI – 400 001.

Sub: Compliance under Clause 41 the Listing Agreement.

Sirs,

Pursuant to Clause 41 of the Listing Agreement, please find enclosed herewith a copy of the Unaudited Financial Results for the period ended on 30th June 2014, as approved by the Board of Directors in their meeting held on even date i.e. 11th August, 2014.

Kindly take the same on record and oblige.

Thanking you,

Yours truly,

For NECTAR LIFESCIENCES LTD.


SUNDER LAL
COMPANY SECRETARY

Encl. as above

CC:- Societe de la Bourse de Luxembourg S.A.
BP 165, L-2011 Luxembourg,
Telephone : (00352) 47 79 38-1
Fax: (00352) 47 32 98



NECTAR LIFESCIENCES LIMITED

Regd. Office: Vill. Saidpura, Tehsil Derabassi, Distt. Mohali, (Punjab)

Part I - Statement of Unaudited Financial Results for the Quarter ended 30.06.2014 (Rs in Lacs)

S. No	PARTICULARS	Quarter ended 30.06.2014	Quarter ended 31.03.2014	Quarter ended 30.06.2013	Year ended 31.03.2014
		Unaudited	Unaudited	Unaudited	Audited
1.	Income from Operations				
	(a) Gross Sales	40213.54	48218.07	36150.94	170818.37
	Less : Excise Duty	2055.75	2177.98	1669.68	7041.45
	Net Sales	38157.79	46040.09	34481.26	163776.92
	(b) Other Operating Income	14.05	34.07	6.53	54.29
	Total Income from Operations (net)	38171.84	46074.16	34487.79	163831.21
2.	Expenses				
	(a) Cost of Materials consumed	25316.14	36725.71	24567.84	117267.14
	(b) Purchase of Stock in Trade	1424.17	147.16	2736.95	3982.32
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(141.56)	(2590.51)	(2948.51)	(5781.06)
	(d) Employee benefits expense	1387.14	1173.69	1398.70	5132.87
	(e) Depreciation and amortisation expense	1923.26	2076.06	2139.51	8418.57
	(f) Other expenses	3612.30	3143.83	2924.94	14353.11
	Total Expenses	33521.45	40675.94	30819.43	143372.95
3.	Profit from Operations before Other Income, finance costs and exceptional items (1-2)	4650.39	5398.22	3668.36	20458.26
4.	Other Income	230.23	90.45	398.86	1162.75
5.	Profit before finance costs and exceptional items (3+4)	4880.62	5488.67	4067.22	21621.01
6.	Finance costs	2840.11	3297.13	2576.78	13798.74
7.	Profit after finance costs but before exceptional items (5-6)	2040.51	2191.54	1490.44	7822.27
8.	Exceptional items	0.00	0.00	0.00	0.00
9.	Profit from ordinary activities before tax (7+8)	2040.51	2191.54	1490.44	7822.27
10.	Tax Expense	415.47	321.88	382.82	1614.28
11.	Net Profit from ordinary activities after tax (9-10)	1625.04	1869.66	1107.62	6207.99
12.	Extraordinary item (net of tax expense)	0.00	0.00	0.00	0.00
13.	Net Profit for the period (11-12)	1625.04	1869.66	1107.62	6207.99
14.	Paid up Equity Share Capital (Face Value per share : Re.1/-)	2,242.61	2,242.61	2,242.61	2,242.61
15.	Reserves excluding Revaluation Reserves	-	-	-	90463.57
16.i	Earnings per Share (EPS) (before extraordinary items)				
	a) Basic	0.72	0.83	0.49	2.77
	b) Diluted	0.72	0.83	0.49	2.77
16.ii	Earnings per Share (EPS) (after extraordinary items)				
	a) Basic	0.72	0.83	0.49	2.77
	b) Diluted	0.72	0.83	0.49	2.77

Part II Select Information for the Quarter ended 30.06.2014

A	Particulars of shareholding				
1.	Public Shareholding				
	- Number of Shares	124,792,970	124,792,970	124,792,970	124,792,970
	- Percentage of Shareholding	55.65	55.65	55.65	55.65
2.	Promoters and Promoter Group Shareholding				
	a) Pledged/Encumbered				
	- Number of Shares	55,555,600	-	-	-
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	55.85	-	-	-
	- Percentage of Shares (as a % of the total share capital of the company)	24.77	-	-	-
	b) Non-encumbered				
	- Number of Shares	43,912,400	99,468,000	99,468,000	99,468,000
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	44.15	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the company)	19.58	44.35	44.35	44.35
B	Investor Complaints	3 Months ended 30.06.2014			
	Pending at the beginning of Quarter				-
	Received During the Quarter				5
	Disposed Off During the Quarter				5
	Pending at the end of Quarter				-

Notes:

- The above financial results were reviewed by Audit Committee on 11.08.2014 and approved by the Board in its meeting held on 11.08.2014 and further limited reviewed by the Statutory Auditors of the Company.
- Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period.
- The above financial results are on stand alone basis.
- The company is exclusively in the pharmaceutical business segment.

Certified to be true copy
For NECTAR LIFESCIENCES LTD.

By Order of the Board of Directors
of Nectar Lifesciences Limited

(Dinesh Dua)

Chief Executive Officer & Director

Dated: 11.08.2014

Place: Chandigarh

SUNDER LAL
COMPANY SECRETARY